Overview
The Borrelia DNA-PCR test uses polymerase chain reaction technology to detect genetic material from Borrelia species in a blood sample. PCR directly identifies Borrelia DNA rather than measuring antibody responses, offering a different perspective from serological testing.
This test may be clinically useful when symptoms or exposure history raise questions about Borrelia presence and antibody-based tests do not provide sufficient clarity. PCR detection can add context in early stages of illness or in situations where antibody responses are delayed, absent or difficult to interpret.
Practitioners typically interpret results alongside symptom history, timing of exposure, previous laboratory findings and consideration of other tick-borne organisms. Reviewing these factors together supports informed discussions with clients about investigation pathways and clinical context.
Indications
- Suspected Lyme disease: symptoms following known or possible tick exposure.
- Acute illness: early flu-like symptoms after a tick bite.
- Persistent symptoms: ongoing joint pain, fatigue or neurological symptoms.
- Serology limitations: inconclusive or conflicting antibody test results.
- Tick exposure history: outdoor or occupational exposure to ticks.
- Complex presentations: symptoms not fully explained by standard testing.
- Co-infection context: consideration of tick-borne pathogens alongside Borrelia.
- Clinical investigation: part of a broader assessment of suspected tick-borne illness.
Practical
2x EDTA
This sample requires a blood draw
Downloads
29-May-2024
27-Nov-2024
27-Nov-2024
29-May-2024
03-Jun-2024
29-May-2024